Key Takeaways
- Revenue in line, margin hit by wage and mix: Revenue of $107.3 million grew 2.4% QoQ CC, but EBITDA margin fell ~100 bps to 14.4% as increments, ESOPs, and a shift toward lower-margin localized work outweighed AI-led efficiency gains.
- UK order book stalled on policy uncertainty: A softer UK order quarter saw contracts put on hold or canceled pending the new government’s budget, even as UK revenue grew 4.1% led by Financial Services.
- Order backlog down 7.7% on deferred starts: The 12-month backlog declined sequentially as clients slowed consumption and a large North America federal deal was delayed until after the midterm elections.
- AI transformation bets are high-margin but small today: AI deals run $0.5M–$5M with 40%+ gross margins, while AI productivity deals are price-aggressive; management is pivoting toward transformation to escape a red ocean.
- What to watch next quarter: Whether the UK budget unlocks stalled orders, the pace of Healthcare & Life Sciences beta-contract wins, and the promised margin recovery in US and Middle East starting Q3.
Revenue & Backlog: The Deferred-Consumption Drag
- Revenue met expectations: $107.3 million with 2.4% QoQ CC growth, described as healthy and very close to expectations on most parameters. All three geographies grew sequentially.
- Order backlog declined 7.7% sequentially: The 12-month backlog fell because of deferred starts and slower consumption of new projects, not because of lost deals.
- North America federal deal delayed: A large deal with the federal government won last quarter was right-shifted until after the midterm elections, directly reducing the 12-month backlog.
- UK deal consuming slower than expected: A won contract in the UK is ramping more slowly than anticipated; management adjusted the backlog accordingly and hopes consumption picks up around Q4.
- Large deal pipeline is the offset: A very healthy pipeline of $100M+ deals in UK-Europe and North America is up for adjudication over the next 6–9 months, any one of which could change the order backlog materially in a single transaction.
Umang Nahata: "There is this trend of consolidating business into larger deals, and we are seeing a very healthy pipe of $100 million plus kinds of deals sitting in our pipeline, which will be adjudicated over the next six to nine months... that's another important factor which can change the order backlog in a single transaction itself. It can impact the numbers sizably."
Margin Walk: Wage Hit, Mix Shift, and the AI Offset
- EBITDA margin fell to 14.4%: The ~100 bps sequential decline had three components: increments and ESOPs took 190 bps, a mix shift from high-margin projects ramping down and being replaced by lower-margin work took ~200 bps, and AI-led internal efficiencies gave back almost 200 bps.
- UK localization is the structural margin headwind: The ask for local security-cleared resources is rising, pushing up the onsite mix and compressing margins; management says recovering this will require a systematic internal change, not a quick fix.
- US and Middle East margin improvement expected from Q3: Management sees an improvement in both geographies starting Q3 itself, which will help recover some of the margin lost in the UK due to mix change.
- Medium-term margin target: The endeavor is to improve EBITDA by at least 160 bps in the medium term, though the velocity of improvement depends on macro and geopolitical factors.
Deepak Kedia: "One factor which I said which basically has dropped the margin is the onsite mix wherein the ask for local security-cleared resources is definitely going up and localization is definitely going up. And we will have to deal with that and that will require a systematic change internally for us to basically recover that."
UK: Strong Revenue, Stalled Orders
- UK revenue grew 4.1% sequentially: Financial Services grew more than 16% in the quarter, and Public Sector saw decent growth supported by momentum and higher working days.
- Healthcare & Life Sciences lagged: Right-shifting in project starts and order book timing hurt the vertical, though some right-shifted orders were concluded post-quarter close.
- Order book hit by government transition: Contracts in the pipeline were put on hold or canceled pending the new government’s budget finalization; management expects momentum to correct as clarity emerges post-budget.
- Energy & Utilities frameworks landed: Three new frameworks were secured in UK-Europe over the last 90–120 days, and contracts are already starting to be won within them.
- UK NHS bridge contract in place: A bridge contract covers the next ~6 months while a large contract north of £10 crore is being bid for; renewal is an H2 event.
North America: Muted H1, H2 Turnaround Bet
- H1 growth was muted: North America revenue performance was soft in the first half, but order book momentum is moving in the right direction.
- Order backlog grew more than 50% YoY: North America order backlog growth was driven by focus on key verticals (Healthcare & Life Sciences, retail, manufacturing) and AI-native transformation deals.
- Meaningful turnaround predicted for H2: Management is sticking to its forecast of a growth turnaround starting in H2, supported by the order book build.
- Federal deal delay is a timing issue, not a loss: The large federal government deal won last quarter is delayed until post-midterm elections; the work is still expected to materialize.
AI Strategy: High-Margin Transformation vs. Red-Ocean Productivity
- AI transformation deals carry 40%+ gross margins: AI foundation and transformation engagements sometimes run north of 50% gross margin, while AI productivity deals are much more price-aggressive with upfront margin compression.
- AI productivity deals are a deliberate three-year bet: Management is committing to deliver 35% to 60–70% productivity on some traditional IT services, accepting lower initial margins with a view to improving them over time.
- Strategy is pivoting toward transformation: The stated focus is to move toward more transformation business, which is sweeter in terms of Mastek’s capability, rather than compete in the red ocean of AI productivity.
- AI deals evolve continuously: Once an AI engagement starts in an account, it evolves into a continuous engagement of delivering more solutions rather than a one-time project.
- AI deal sizes are small today, expected to grow in pieces: Current AI deals run between $0.5 million and $5 million; transformative deals are expected to evolve into larger engagements in pieces rather than one large deal at a go.
- AI revenue disclosure coming next quarter: Management will begin outlining and presenting AI revenue numbers starting next quarter, with a Data & AI horizontal lens on the organization.
Umang Nahata: "Hence, the focus is to move towards more and more transformation business, which is much sweeter in terms of Mastek’s capability than just compete on the AI productivity, which is clearly a red ocean."
Verticals & Geographies: BFSI Strong, Healthcare Timing Gap, Middle East Uncertain
| Vertical / Geography | Trend | Commentary |
|---|---|---|
| BFSI | ▲ Strong | Growth largely orchestrated by UK-Europe with modern data work; North America financial services seeing good openings and new logos but still early stages. |
| Healthcare & Life Sciences | ▼ Soft | Softness from UK-Europe; projects finished alpha phase and recontracting for beta took longer than anticipated, especially on the government side; also saw ramp-down in one traditional offshore account. |
| UK Financial Services | ▲ Grew 16%+ | Robust quarter driven by modern data deals including Bank of England and Financial Conduct Authority. |
| APAC & Middle East | ▼ Uncertain | Uncertainty continues and is getting more stringent; decent Q2 bounce from old standing contracts being signed, but outlook remains uncertain, especially with the situation in Saudi Arabia. |
| Oracle business | ▲ Healthy | Net-new traction in North America and UK & Europe; also winning AI-led managed services delivering productivity on Oracle. |
| Energy & Utilities | ▲ Building | Three new frameworks landed; contracts starting to be won within them; management will report progress as the year goes forward. |
- Healthcare recovery expected in H2: Most beta contracts have been bid for; results are expected in Q3 or latest early Q4, and management is confident the vertical will bounce back and continue to be one of the strongest growth engines.
- Middle East running significantly behind plan: The region is being managed by UK and US performance, but the situation remains out of management’s control.
People, Cash, and Operations
- Headcount reduced by 87: The decline was due to workforce restructuring and a change in onsite/offshore mix; utilization including trainees fell 0.8% sequentially because of investment in domain resources.
- Attrition down for second consecutive quarter: LTM attrition fell from 16.4% to 15.2%, a decline of 1.2 percentage points.
- Cash collection was strong: $120 million collected in the quarter; DSO of 74 days, down 1 day, reflecting strong cash management and aggressive collection initiatives.
- Exceptional items were net-neutral: Profit from the sale of a Chennai property was offset by workforce restructuring costs due to AI-led efficiencies and a write-off of old receivables, both one-time in nature.
- Subcon costs stable: Currently at the traditional 18%–20% of revenue; UK localization pressure may require short-term subcon hiring, to be replaced by FTEs eventually, and is not expected to go extravagantly higher than 20% in the long run.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | H2 performance should continue to do well; FY27 will do better than FY26 | FY27 full year |
| North America growth | Meaningful turnaround in growth momentum | Starting H2 FY27 |
| EBITDA margin recovery | Improve by at least 160 bps in the medium term; US and Middle East margin improvement starting Q3 | Medium term; Q3 for US/ME |
| Healthcare & Life Sciences recovery | Beta contracts awarded and ramp back up; vertical bounces back as one of strongest growth engines | Q3 to early Q4 FY27 |
| UK public sector order booking | Momentum corrects as clarity emerges post budget announcement | Post-UK budget (imminent) |
| AI revenue disclosure | Start outlining and presenting AI revenue numbers; Data & AI horizontal lens on organization | Starting next quarter (Q3 FY27) |
| UK NHS large contract | North of £10 crore deal bid for; would be addition to current TCV | H2 FY27 event |
| Large deal pipeline | $100M+ deals in UK-Europe and North America to be adjudicated | Next 6–9 months |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | $107.3 million, +2.4% QoQ in constant currency |
| Revenue (INR) | ₹1,018.7 crore, +3.4% QoQ and +8.3% YoY |
| Operating EBITDA margin | 14.4%, down 100 bps QoQ; increments and ESOPs had 190 bps impact, partially offset by AI-led efficiencies and additional working days |
| PAT | ₹105.7 crore, 10.3% of total income |
| Basic EPS | ₹34.1, up 8.3% YoY |
| Diluted EPS | ₹33.9, up 8.4% YoY |
| 12-month order backlog | $286.2 million, -7.7% QoQ and +2.3% YoY in USD; +10.4% YoY in INR |
| UK revenue growth | 4.1% QoQ |
| UK EBIT | 18% |
| North America total backlog growth | +7.8% QoQ and +47.9% YoY |
| AI deals as a percentage of total order book | ~45% (53 AI orders closed in the quarter) |
| Public sector sequential growth | 6.1% |
| Financial Services sequential growth | 15.3% |
| DSO | 74 days, a decrease of 1 day |
| Closing cash and investments net of debt | ₹582.7 crore, after ₹50 crore dividend and ~₹55 crore loan repayment; net addition of ~₹36 crore during the quarter |
| Total headcount | 4,810, a reduction of 87 |
| Last 12-month attrition | 15.2%, down from 16.4% (a 1.2% decline) |
| Utilization including trainees | Down 0.8% sequentially |
| New customers added | 18, versus 13 in the previous quarter |
| Project business as a percentage of total revenues | 44%–45%, up from 40% |
| Subcon cost as a percentage of revenue | ~18%–20%, may move up or down by 1 ppt in the short term |
| Healthcare vertical decline over the last year | Down more than 25% (per an analyst's math) |